ScholarIQanswers from OpenAlex
Sphingolipid Metabolism and Signaling
TopicLeading institutions, researchers & key papers
Sphingolipid Metabolism and Signaling is a topic indexed in ScholarIQ from OpenAlex.
What is known about Sphingolipid Metabolism and Signaling?
ScholarIQrecord summary
This cluster of papers explores the role of sphingolipids, including sphingosine-1-phosphate and ceramide, in signaling and metabolism, with implications for health and disease such as lymphocyte egress, insulin resistance, cancer, and apoptosis.
How many works does Sphingolipid Metabolism and Signaling have?
ScholarIQindexed works
Sphingolipid Metabolism and Signaling has 113 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Sphingolipid Metabolism and Signaling?
ScholarIQopenalex
The OpenAlex for Sphingolipid Metabolism and Signaling is on the source record.
What are the most-cited papers on Sphingolipid Metabolism and Signaling?
ScholarIQmost cited works
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
Marcel Verheij, Ron Bose, Xin Lin, Bei Yao, W. David Jarvis, Steven Grant, Michael J. Birrer, Éva Szabó, Leonard I. Zon, John Kyriakis, Adriana Haimovitz‐Friedman, Zvi Fuks, Richard Kolesnick
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol
Reijo Laaksonen, Kim Ekroos, Marko Sysi‐Aho, Mika Hilvo, Terhi Vihervaara, Dimple Kauhanen, Matti Suoniemi, Reini Hurme, Winfried März, Hubert Scharnagl, Tatjana Stojaković, Efthymia Vlachopoulou, Marja‐Liisa Lokki, Markku S. Nieminen, Roland Klingenberg, Christian M. Matter, Thorsten Hornemann, Peter Jüni, Nicolas Rodondi, Lorenz Räber, Stephan Windecker, Bariş Gencer, Eva Ringdal Pedersen, Grethe S. Tell, Ottar Nygård, François Mach, Juha Sinisalo, Thomas F. Lüscher
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin, David H. Miller, Mark S. Freedman, Bruce Cree, Jerry S. Wolinsky, Howard L. Weiner, Catherine Lubetzki, Hans‐Peter Hartung, Xavier Montalbán, Bernard M.J. Uitdehaag, Martin Merschhemke, Bingbing Li, Norman Putzki, Fonda Liu, Dieter A. Häring, Ludwig Kappos
Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea)
Dong D. Wang, Estefanía Toledo, Adela Hruby, Bernard Rosner, Walter C. Willett, Qi Sun, Cristina Razquín, Yan Zheng, Miguel Ruiz‐Canela, Marta Guasch‐Ferré, Dolores Corella, Enrique Gómez‐Gracia, Miquel Fiol, Ramón Estruch, Emilio Ros, José Lapetra, Montserrat Fitó, Fernando Arós, Luís Serra‐Majem, Chih‐Hao Lee, Clary B. Clish, Liming Liang, Jordi Salas‐Salvadó, Miguel Ángel Martínez‐González, Frank B. Hu
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
Eugen Ruckhäberle, Achim Rody, Knut Engels, R. Gaetje, Gϋnter von Minckwitz, Susanne Schiffmann, Sabine Grösch, Gerd Geißlinger, Uwe Holtrich, Thomas Karn, Manfred Kaufmann
Where is Sphingolipid Metabolism and Signaling research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Sphingolipid Metabolism and Signaling is open access?
ScholarIQopen access share
73%OPEN ACCESS